Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I mass balance and metabolite profiling study of cilengitide in healthy volunteers
NL-OMON37147Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cilengitide in cancer, sponsored by Merck & Co. Primary endpoints: Mass balance of total 14C radioactivity, Urinary and fecal excretion and 2 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
cilengitide
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON37147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37147.